Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results

Su, Li; Huang, He; Liao, Hai; Zhan, Jing; Guo, Yin; Zou, Ben Yan; Jiang, Wen Qi; Guan, Zhong; Yang, Xu

doi:10.5414/cp201761

Cited by 8 publications

(4 citation statements)

References 11 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, while dicycloplatin in clinical trials was administered to patients via an intravenous infusion, 28,29 there is a recent case report of the successful treatment of a patient using a hard capsule formulation of dicycloplatin for oral administration. 30 The result is surprising given the high acid concentration in the stomach, which is likely to protonate the carboxylate ligands and facilitate their early release from the drug.…”

Section: Perspective Dalton Transactionsmentioning

confidence: 99%

A chemical perspective on the clinical use of platinum-based anticancer drugs

Alassadi

Pisani²,

Wheate

2022

Dalton Trans.

View full text Add to dashboard Cite

show abstract

Section: Perspective Dalton Transactionsmentioning

confidence: 99%

A chemical perspective on the clinical use of platinum-based anticancer drugs

Alassadi

Pisani²,

Wheate

2022

Dalton Trans.

View full text Add to dashboard Cite

show abstract

“…This compound is composed of one molecule of carboplatin and one molecule of cyclobutane-1,1-dicarboxylic acid interacting via hydrogen bonds (see Chart 1). 16 The mechanism by which the presence of free ligand affects the activity of this platinum drug is not clear.…”

Section: Metal-based Anticancer Drugsmentioning

confidence: 99%

Exploration of the medical periodic table: towards new targets

2013

View full text Add to dashboard Cite

Metallodrugs offer potential for unique mechanisms of drug action based on the choice of the metal, its oxidation state, the types and number of coordinated ligands and the coordination geometry. We discuss recent progress in identifying new target sites and elucidating the mechanisms of action of anti-cancer, anti-bacterial, anti-viral, anti-parasitic, anti-inflammatory, and anti-neurodegenerative agents, as well as in the design of metal-based diagnostic agents. Progress in identifying and defining target sites has been accelerated recently by advances in proteomics, genomics and metal speciation analysis. Examples of metal compounds and chelating agents (enzyme inhibitors) currently in clinical use, clinical trials or preclinical development are highlighted.

show abstract

“…The cause and clinical significance of these toxicities need to be assessed and confirmed in further studies. In addition, a recent phase I study of dicycloplatin demonstrated a favorable safety profile at doses between 50 mg/m 2 and 550 mg/m 2 [28], which permitted clinical trials with more patient samples in future.…”

Section: Discussionmentioning

confidence: 99%

A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancers

Liu¹,

Guan²,

Liang³

et al. 2014

aoms

Self Cite

View full text Add to dashboard Cite

IntroductionThe aim of this study was to compare the efficacy and toxicity of dicycloplatin plus paclitaxel with those of carboplatin plus paclitaxel as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC).Material and methodsIn this study, 240 NSCLC patients with stage IIIB (with pleural effusion) and stage IV disease were randomly assigned (1: 1) to receive dicycloplatin 450 mg/m2 or carboplatin AUC = 5, in combination with paclitaxel 175 mg/m2 (D + P or C + P) every 3 weeks for up to 4 to 6 cycles. The primary endpoint was response rate. Secondary endpoints included progression-free survival (PFS), overall survival (OS) and adverse events.ResultsThe response rates for the D + P and C + P arm were 36.44% and 30.51%, respectively (p = 0.33). The median PFS was 5.6 months in the D + P arm and 4.7 months in the C + P arm (p = 0.31). The median OS was 14.9 months for D + P and 12.9 months for C + P (p = 0.37). Adverse events in the two arms were well balanced. The most common grade 3/4 adverse event was hematologic toxicity.ConclusionsPatients treated with D + P had similar response and survival rates to those treated with C + P, and toxicities of both treatments were generally tolerable.

show abstract

Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results

Abstract: DCP displayed a favorable safety profile at doses between 50 mg/m(2) and 550 mg/m(2), and first efficacy signals were observed. DLTs were thrombocytopenia, anemia and emesis. The recommended starting dose for a subsequent Phase II study is 450 mg/m(2) once every 3 weeks.

Cited by 8 publications

References 11 publications

A chemical perspective on the clinical use of platinum-based anticancer drugs

A chemical perspective on the clinical use of platinum-based anticancer drugs

Exploration of the medical periodic table: towards new targets

A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancers

Contact Info

Product

Resources

About